Law Offices of Howard G. Smith Encourages Novo Nordisk A/S (NVO) Investors To Inquire About Securities Fraud Class Action
IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN NOVO NORDISK A/S (NVO), CONTACT THE LAW OFFICES OF HOWARD G. SMITH TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT.
Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at howardsmith@howardsmithlaw.com, by telephone at (215) 638-4847 or visit our website at www.howardsmithlaw.com.
What Happened?
On July 29, 2025, Novo Nordisk cut its previously issued fiscal year 2025 guidance, lowering sales growth from 13-21% to 8-14%, and operating profit from 16-24% to 10-16%. The Company cited lower growth expectations for both Ozempic and Wegovy on the back of a slowdown in market expansion, competition, and the alleged continued use of compounded GLP-1s.
On this news, Novo Nordisk's stock price fell $15.06, or 21.8%, to close at $53.94 per share on July 29, 2025, thereby injuring investors.
What Is The Lawsuit About?
The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Novo Nordisk repeatedly ignored and minimized the significance of the personalization exception for GLP-1 compounding, greatly overestimated its ability to capture patients coming off of compounded treatments, and was ultimately ill equipped to capitalize upon the purported significant unmet patient population; and (2) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.
Contact Us To Participate or Learn More:
If you purchased Novo Nordisk securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us:
Law Offices of Howard G. Smith,
3070 Bristol Pike, Suite 112,
Bensalem, Pennsylvania 19020,
Telephone: (215) 638-4847
Email: howardsmith@howardsmithlaw.com,
Visit our website at: www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
18 minutes ago
- Globe and Mail
Digital Silk Oversees Website Redesign for Urbanna Landscaping to Reflect Brand Growth and Support Client Conversion
New York, New York--(Newsfile Corp. - August 8, 2025) - Digital Silk, an award-winning agency focused on creating brand strategies, custom websites, and digital marketing campaigns, has completed a website redesign project for Urbanna Landscaping, a New Jersey-based landscaping company with over 30 years of industry experience. The project aimed to realign the brand's online presence with its expanded service offerings and growing clientele. Website Redesign for Urbanna Landscaping To view an enhanced version of this graphic, please visit: Website Redesign Aligns with Business Expansion Urbanna Landscaping approached Digital Silk to update its website architecture, visuals, and messaging to better reflect its evolution from a residential landscape service provider to a full-service partner for commercial and municipal clients. The redesigned site features modern layouts, optimized navigation, and clearly defined service pathways to support client acquisition and engagement. The restructured user experience was developed to support faster access to Urbanna's portfolio, community initiatives, and expanded commercial services, while improving mobile responsiveness and lead-generation opportunities across devices. User Experience and Functionality Improvements According to a 2024 study by GoodFirms, 73.1% of users say they leave a website with a non-responsive design. Digital Silk's redesign focused on responsive page layouts and simplified contact pathways that may support higher engagement and reduce bounce rates. Key updates to the Urbanna Landscaping website include: Reorganized sitemap with clearly defined commercial and residential service categories Visual emphasis on team, leadership, and certifications to support trust Integrated project showcase highlighting award-winning landscape work Streamlined navigation to encourage quote requests and contact form completions On-brand visuals optimized for performance across modern devices CEO Commentary on Brand Consistency "Brands that have evolved over decades often need their websites to reflect new capabilities and customer expectations," said Gabriel Shaoolian, CEO of Digital Silk. "This redesign project focused on building a more strategic digital presence that supports Urbanna's continued growth." The updated website is now live and serves as the foundation for Urbanna Landscaping's next phase of business development. More information is available at: About Digital Silk Digital Silk is an award-winning New York Web Development Agency focused on growing brands online. With a team of seasoned experts, Digital Silk delivers industry-leading digital experiences through strategic branding, custom web design, and digital marketing services to help improve visibility and support engagement.
Globe and Mail
18 minutes ago
- Globe and Mail
SKYX Updates Time of Corporate Update Call to 4:30 PM ET on August 12, 2025
Company to Provide Corporate Updates Including New Developments, Second Quarter 2025 Overview and Financial Results; Conference Call to be Held Tuesday, August 12, 2025, at 4:30 PM Eastern Time Time of Event changed from 10:00 AM EST to 4:30 PM EST MIAMI, Aug. 08, 2025 (GLOBE NEWSWIRE) -- SKYX Platforms Corp. (NASDAQ: SKYX) (d/b/a "SKYX Technologies"), a highly disruptive advanced and smart home platform technology company for homes and buildings, with more than 100 issued and pending patents globally and a portfolio of over 60 lighting and home décor websites, announces today that it will host a Corporate Update call and present its second quarter 2025 overview and financial results. The conference call will be held on Tuesday, August 12, 2025, at 4:30 p.m. Eastern Time. SKYX Participating Members will include: Rani Kohen, Founder and Executive Chairman Steve Schmidt, SKYX President, (former CEO of Nielsen Data Corporation and former President of Office Depot International) Lenny Sokolow, Co-CEO SKYX Platforms – Q2 2025 Date: Tuesday, August 12, 2025 Time: 4:30 PM Eastern Time U.S./Canada Dial-in: 1-412-317-5180 International Dial-in: 1-844-825-9789 Call me™ link for instant telephone access to the event: Passcode: 1488921 Please dial in at least 10 minutes before the start of the call to ensure timely participation. Webcast link: A playback of the call will be available until September 12, 2025. Replay Dial-In: 1-844-512-2921 or 1-412-317-6671 Replay Pin Number: 10202040 About SKYX Platforms Corp. As electricity is a standard in every home and building, our mission is to make homes and buildings become safe-advanced and smart as the new standard. SKYX has a series of highly disruptive advanced-safe-smart platform technologies, with over 100 U.S. and global patents and patent pending applications. Additionally, the Company owns over 60 lighting and home decor websites for both retail and commercial segments. Our technologies place an emphasis on high quality and ease of use, while significantly enhancing both safety and lifestyle in homes and buildings. We believe that our products are a necessity in every room in both homes and other buildings in the U.S. and globally. For more information, please visit our website at or follow us on LinkedIn. Forward-Looking Statements Certain statements made in this press release are not based on historical facts, but are forward-looking statements. These statements can be identified by the use of forward-looking terminology such as "aim," "anticipate," "believe," "can," "could," "continue," "estimate," "expect," "evaluate," "forecast," "guidance," "intend," "likely," "may," "might," "objective," "ongoing," "outlook," "plan," "potential," "predict," "probable," "project," "seek," "should," "target" "view," "will," or "would," or the negative thereof or other variations thereon or comparable terminology, although not all forward-looking statements contain these words. These statements reflect the Company's reasonable judgment with respect to future events and are subject to risks, uncertainties and other factors, many of which have outcomes difficult to predict and may be outside our control, that could cause actual results or outcomes to differ materially from those in the forward-looking statements. Such risks and uncertainties include statements relating to the Company's ability to successfully launch, commercialize, develop additional features and achieve market acceptance of its products and technologies and integrate its products and technologies with third-party platforms or technologies; the Company's efforts and ability to drive the adoption of its products and technologies as a standard feature, including their use in homes, hotels, offices and cruise ships; the Company's ability to capture market share; the Company's estimates of its potential addressable market and demand for its products and technologies; the Company's ability to raise additional capital to support its operations as needed, which may not be available on acceptable terms or at all; the Company's ability to continue as a going concern; the Company's ability to execute on any sales and licensing or other strategic opportunities; the possibility that any of the Company's products will become National Electrical Code (NEC)-code or otherwise code mandatory in any jurisdiction, or that any of the Company's current or future products or technologies will be adopted by any state, country, or municipality, within any specific timeframe or at all; risks arising from mergers, acquisitions, joint ventures and other collaborations; the Company's ability to attract and retain key executives and qualified personnel; guidance provided by management, which may differ from the Company's actual operating results; the potential impact of unstable market and economic conditions on the Company's business, financial condition, and stock price; and other risks and uncertainties described in the Company's filings with the Securities and Exchange Commission, including its periodic reports on Form 10-K and Form 10-Q. There can be no assurance as to any of the foregoing matters. Any forward-looking statement speaks only as of the date of this press release, and the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by U.S. federal securities laws.
Globe and Mail
27 minutes ago
- Globe and Mail
Hologic's Diagnostics Arm Set for Long-Term Upside: What's Behind It?
Hologic 's HOLX Diagnostics unit, the largest by revenues, has been the most impacted by geopolitical headwinds this year. Cuts in USAID funding have affected its HIV testing business in Africa, while a challenging operating environment in China has weighed on its Cytology business. As a result, Diagnostics posted just 0.9% year-over-year reported growth in the third quarter of fiscal 2025. Despite these hurdles, the underlying growth drivers in the segment continue to remain strong. One is the BV, CV/TV assay, which has become Hologic's second-largest assay globally after shifting from a primarily lab-developed test (LDT) approved in 2019 to an in-vitro diagnostics (IVD) test on the high-throughput Panther instrument. The company is working to reach the estimated 60% of U.S. women who are not tested when they experience vaginitis, applying the same approach it uses to expand sexually transmitted infection (STI) testing. Additionally, Panther Fusion, an add-on module to the base Panther platform, is gaining nice traction this year as customers adopt more menus. The system uses PCR chemistry to run Hologic's suite of respiratory assays, including influenza, while offering an expanded IVD menu and Open Access functionality for LDTs. Open Access testing kits contributed to Fusion's solid growth in the fiscal third quarter. Over the next several years, Hologic plans to broaden the menu by launching an IVD test for GI and hospital-acquired infections, positioning the sidecar to play a key role in future Diagnostics growth. The company is also currently in the early stages of its Biotheranostics opportunity. Acquired in 2021, the asset marked Hologic's entry into the lab-based oncology space, an expanding and longtime area of interest. Biotheranostics' Breast Cancer Index test — the only commercially available test validated to inform the decision regarding extended endocrine therapy — continues to see strong adoption. Latest Updates From Hologic's Diagnostics Peers Abbott 's ABT Diagnostics sales declined 1.5% in the second quarter of 2025, mainly due to the year-over-year decrease in COVID-19 testing sales and the impact of volume-based procurement programs in China. Together, these are expected to weigh on ABT's full-year Diagnostics sales growth by around $700 million or 750 basis points. Excluding China, Abbott's Core Lab Diagnostics grew 8%, reflecting strong underlying demand in the global markets. Danaher 's DHR core sales growth in the molecular diagnostics business witnessed growth in the second quarter of 2025, as gains in non-respiratory testing more than offset declines in core sales of respiratory tests. Danaher also announced a new partnership with AstraZeneca to develop diagnostic tools that identify patients most likely to benefit from precision medicine treatments. This collaboration is leveraging the newly launched Danaher Centers to enable precision medicine to streamline the end-to-end development process. HOLX Stock Performance, Valuation and Estimates Year to date, Hologic shares have declined 5.8% compared with the industry's 11.7% fall. Hologic is trading at a forward five-year price-to-earnings of 15.05X, lower than the industry average of 27.49X. The stock carries a Value Score of B at present. Image Source: Zacks Investment Research See how analysts are projecting Hologic's EPS for fiscal 2025 and 2026. HOLX stock currently carries a Zacks Rank #3 (Hold).You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. See our %%CTA_TEXT%% report – free today! 7 Best Stocks for the Next 30 Days Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Danaher Corporation (DHR): Free Stock Analysis Report Hologic, Inc. (HOLX): Free Stock Analysis Report This article originally published on Zacks Investment Research (
